Tags : Clinical

Clinical Trials COVID-19

Pfizer and BioNTech’s BNT162b2 Demonstrates 90% Efficacy in Preventing COVID-19

Shots: The BNT162b2 showed more than 90% efficacy in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis, conducted on Nov 8, 2020 from P-III clinical study The companies reported no serious safety concerns so far while safety and additional efficacy data continues to be collected. The company […]Read More

Clinical Trials COVID-19

Celltrion Reports Results of CT-P59 in P-I Study for COVID-19

Shots: The P-I clinical trial involves assessing CT-P59 (20/40/80 mg/kg) vs PBO in 18 patients with mild symptoms of SARS-COV-2 infection who were randomized into 3 cohorts Results: patients demonstrated a 44% reduction in mean clinical recovery time, while no patients required hospitalization or antiviral therapy Celltrion has submitted the IND application for the clinical […]Read More

Pharma

Thermo Fisher Expands its Direct-to-Patient Service Offerings

Shots: The company has expanded its Direct-to-Patient service offerings for supporting decentralized clinical trials to lessen clinical trial lengths and costs while increasing patient enrollment and participation rates The company’s expanded Direct-to-Patient services build on its global Clinical Site-to-Patient program that launched in early 2020 to ensure that clinical trial patients have uninterrupted access to […]Read More

Biotech

GSK Presents Results of Maternal & Older Adults RSV Vaccines

Shots: GSK reported that its RSV vaccines for maternal immunization (GSK3888550A) and older adults (GSK3844766A) were well-tolerated and highly immunogenic in P-I/II clinical studies. Both the candidate vaccines contain a recombinant RSVPreF3, that triggers the required immune response The GSK3844766A was first tested in 48 healthy adults (18-40yrs.) & then in 1005 healthy older adults […]Read More

Clinical Trials

Roche and Prothena to Advance Prasinezumab in P-IIb Study for

Shots: The companies will advance the prasinezumab into a P-IIb study in patients with early Parkinson’s disease based on positive signals of efficacy consistent with disease modification in the PASADENA study The study is designed to further assess the efficacy of prasinezumab by expanding upon the patient population enrolled in PASADENA study to include patients […]Read More

Clinical Trials COVID-19

Eli Lilly Pauses Enrollment in ACTIV-3 Clinical Trial Due to

Shots:  The independent DSMB recommended pausing the enrollment of the ACTIV-3 clinical trial. The trial is evaluating Lilly’s bamlanivimab (LY-CoV555, 7000mg) + remdesivir as a treatment for COVID-19 in hospitalized patients, and is sponsored by the NIAID Lilly trusts the judgment & supports independent DSMB decisions to exercise caution in ensuring the safety of the […]Read More

Pharma

Nektar Therapeutics Signs a Clinical Trial Collaboration with Bristol-Myers Squibb

Shots: The collaboration will evaluate Nektar Therapeutics’ bempegaldesleukin in combination with BMS’ Opdivo (nivolumab) into multiple new registrational trials and the cost of trials will be shared upon the cost-sharing outlined in the terms of the original collaboration agreement The companies have expanded their collaboration for bempeg + nivolumab from three ongoing registrational trials targeted […]Read More